Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1991-4-25
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0077-8923
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
616
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
201-4
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:2127663-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:2127663-Animals,
pubmed-meshheading:2127663-Antiviral Agents,
pubmed-meshheading:2127663-Cost-Benefit Analysis,
pubmed-meshheading:2127663-Drug Evaluation, Preclinical,
pubmed-meshheading:2127663-Oligonucleotides, Antisense
|
pubmed:year |
1990
|
pubmed:articleTitle |
Antisense and antiviral therapy.
|
pubmed:affiliation |
Department of Cell Biology, Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 07110.
|
pubmed:publicationType |
Journal Article,
Review
|